1. Home
  2. MI vs ONCO Comparison

MI vs ONCO Comparison

Compare MI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NFT Limited

MI

NFT Limited

HOLD

Current Price

$7.95

Market Cap

3.4M

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.89

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MI
ONCO
Founded
2009
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
2.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
MI
ONCO
Price
$7.95
$0.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.4K
225.7K
Earning Date
05-07-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.80
EPS
N/A
N/A
Revenue
N/A
$815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.09
52 Week High
$19.84
$6.73

Technical Indicators

Market Signals
Indicator
MI
ONCO
Relative Strength Index (RSI) 42.06 52.11
Support Level $3.55 $0.64
Resistance Level $10.38 $0.94
Average True Range (ATR) 0.98 0.11
MACD -0.07 0.01
Stochastic Oscillator 26.32 69.17

Price Performance

Historical Comparison
MI
ONCO

About MI NFT Limited

NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: